A Phase 2 interventional study of Simeprevir and Daclatasvir in Hepatitis C, Chronic, sponsored by Janssen R&D Ireland. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-21.
Sponsored by Janssen R&D Ireland (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing simeprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Simeprevir · Hepatitis C, Chronic.
Among the 21 studies testing simeprevir in Hepatitis C, Chronic, this one is the 18th largest by enrollment, is one of 5 that started in 2013, is one of 9 in phase 2, and was the 11th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 21 studies testing simeprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
Simeprevir: first FDA approval 2013 (OLYSIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2013.
This study's enrollment of 35 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 93 across the 21 interventional studies. Of the 20 that completed or were terminated, 13 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen R&D Ireland, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen R&D Ireland is the lead sponsor of 32 studies on the registry; none are open to participants now.
30 studies in Hepatitis C, Chronic by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 30 finished, 18 (60%) have results posted.
Among the 30 studies in Hepatitis C, Chronic by Johnson & Johnson, this one is the 25th largest by enrollment, is one of 3 that started in 2013, is one of 13 in phase 2, and was the 21st registered.
Johnson & Johnson’s Hepatitis C, Chronic studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing simeprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 30 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate effect of steady-state (when the amount of drug administered (in a given time period is equal to the amount of drug eliminated in that same period) of simeprevir and daclatasvir on the steady-state pharmacokinetics (what a medication does to the body) of cyclosporine (applicable to Part 1 only) and tacrolimus when administered as a combinational regimen in post-orthotopic liver transplantation (OLT) participants with recurrent hepatitis C virus (HCV) genotype 1b infection and effectiveness of a 24-week treatment regimen containing simeprevir, daclatasvir, and ribavirin (RBV) with respect to the proportion of HCV genotype 1b infected post-OLT participants achieving sustained virologic response 12 weeks after end of treatment.
This is an open-label (all participants of this study know the identity of the intervention) and multicenter (study conducted at multiple sites) study. This study will be conducted in 2 parts. Both the parts of the study will consist of screening phase (4 weeks), treatment period (24 weeks), and a post-treatment follow-up (24 weeks). A total of 30 participants will be enrolled in Part 1 and Part 2 of the study. A minimum of 9 participants were planned to receive cyclosporine as stable immunosuppressant therapy and a minimum of 9 participants were planned to receive tacrolimus as stable immunosuppressant therapy during Part 1. All participants will be receiving tacrolimus as stable immunosuppressant therapy during Part 2. In Part 1 of the study, participants with Metavir score of F1-F2, will receive a combination of study drugs - simeprevir, daclatasvir, and ribavirin for 24 weeks. In Part 2 of the study, participants with Metavir score F1-F4 will receive a dosing regimen of study drugs based on the data from Part 1 of the study. Safety evaluations will include assessments of adverse events, clinical laboratory tests, urinalysis, electrocardiogram, vital signs, and physical examination. The total study duration for each participant will be approximately 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
Drug: Simeprevir · Drug: Daclatasvir · Drug: Ribavirin · Drug: Cyclosporine · Drug: Tacrolimus
Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
Drug: Simeprevir · Drug: Daclatasvir · Drug: Ribavirin · Drug: Tacrolimus
Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12)
Participants were considered to have achieved SVR12 if hepatitis C virus ribonucleic acid (HCV RNA) levels were less than (\<) 25 international unit per milliliter (IU/mL) detectable or undetectable at 12 weeks after the end of treatment.
Time frame: Week 36
Percentage of Participants With Sustained Virologic Response 4 Weeks After the End of Treatment (SVR 4)
Participants were considered to have achieved SVR4 if HCV RNA levels were (\<) 25 IU/mL detectable or undetectable at 4 weeks after the end of treatment.
Time frame: Week 28
Percentage of Participants With Sustained Virologic Response 24 Weeks After the End of Treatment (SVR 24)
Participants were considered to have achieved SVR 24 if hepatitis C virus ribonucleic acid (HCV RNA) levels were (\<) 25 IU/mL detectable or undetectable at 24 weeks after the end of treatment.
Time frame: Week 48
Percentage of Participants With HCV RNA (< 25 IU/mL Undetectable) and HCV RNA < 25 IU/mL Detectable
Percentage of participants with detectable and undetectable HCV RNA (\<) 25 IU/mL during treatment at Weeks 2,4, 12, and 24 were reported.
Time frame: Weeks 2, 4, 12, and 24
Percentage of Participants With HCV RNA (<) 100 IU/mL at Week 4
Percentage of participants with HCV RNA (\<) 100 IU/mL at week 4 were reported.
Time frame: Week 4
Number of Participants With On-Treatment Failure
On-treatment failure is defined as participants who did not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of treatment. This was to include participants with: 1) Viral breakthrough, defined as a confirmed increase of greater than (\>)1 log10 in HCV RNA from nadir, or confirmed HCV RNA of \>100 IU/mL in participants whose HCV RNA had previously been \<lower limit of quantification (LLOQ) while on treatment; 2) Other with confirmed detectable HCV RNA at the actual end of treatment (example, completed, discontinued due to adverse events (AEs), withdrawal of consent).
Time frame: Up to Week 24 after actual EOT (week 24)
Number of Participants With Viral Breakthrough
Viral breakthrough is defined as a confirmed increase of \>1 log10 IU/mL in HCV RNA level from the lowest level reached, or a confirmed HCV RNA level of \>100 IU/mL in participants whose HCV RNA levels had previously been below the limit of quantification (\<25 IU/mL detectable) or undetectable (\<25 IU/mL undetectable) while on study treatment.
Time frame: Up to week 24
Number of Participants With Viral Relapse
Participants who did not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (\>=) LLOQ during follow-up.
Time frame: Up to Week 24 after actual EOT (week 24)
| Milestone | Cyclosporine | Tacrolimus |
|---|---|---|
| Started | 10 | 25 |
| Completed | 10 | 23 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
Participants were considered to have achieved SVR12 if hepatitis C virus ribonucleic acid (HCV RNA) levels were less than (\<) 25 international unit per milliliter (IU/mL) detectable or undetectable at 12 weeks after the end of treatment.
| percentage of participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12) | 100 (69.2 to 100) | 88 (68.8 to 97.5) |
Participants were considered to have achieved SVR4 if HCV RNA levels were (\<) 25 IU/mL detectable or undetectable at 4 weeks after the end of treatment.
| percentage of participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 4 Weeks After the End of Treatment (SVR 4) | 100 (69.2 to 100) | 88 (68.8 to 97.5) |
Participants were considered to have achieved SVR 24 if hepatitis C virus ribonucleic acid (HCV RNA) levels were (\<) 25 IU/mL detectable or undetectable at 24 weeks after the end of treatment.
| percentage of participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response 24 Weeks After the End of Treatment (SVR 24) | 100 (69.2 to 100) | 88 (68.8 to 97.5) |
Percentage of participants with detectable and undetectable HCV RNA (\<) 25 IU/mL during treatment at Weeks 2,4, 12, and 24 were reported.
| percentage of participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Week 2: <25 IU/mL detectable | 30 | 36 |
| Week 2: <25 IU/mL undetectable | 10 | 12 |
| Week 4: <25 IU/mL detectable | 30 | 24 |
| Week 4: <25 IU/mL undetectable | 70 | 68 |
| Week 12: <25 IU/mL detectable | 0 | 0 |
| Week 12: <25 IU/mL undetectable | 100 | 96 |
| Week 24: <25 IU/mL detectable | 0 | 0 |
| Week 24: <25 IU/mL undetectable | 100 | 100 |
Percentage of participants with HCV RNA (\<) 100 IU/mL at week 4 were reported.
| percentage of participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Percentage of Participants With HCV RNA (<) 100 IU/mL at Week 4 | 100 | 100 |
On-treatment failure is defined as participants who did not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of treatment. This was to include participants with: 1) Viral breakthrough, defined as a confirmed increase of greater than (\>)1 log10 in HCV RNA from nadir, or confirmed HCV RNA of \>100 IU/mL in participants whose HCV RNA had previously been \<lower limit of quantification (LLOQ) while on treatment; 2) Other with confirmed detectable HCV RNA at the actual end of treatment (example, completed, discontinued due to adverse events (AEs), withdrawal of consent).
| participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Number of Participants With On-Treatment Failure | 0 | 3 |
Viral breakthrough is defined as a confirmed increase of \>1 log10 IU/mL in HCV RNA level from the lowest level reached, or a confirmed HCV RNA level of \>100 IU/mL in participants whose HCV RNA levels had previously been below the limit of quantification (\<25 IU/mL detectable) or undetectable (\<25 IU/mL undetectable) while on study treatment.
| participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Number of Participants With Viral Breakthrough | 0 | 3 |
Participants who did not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (\>=) LLOQ during follow-up.
| participants | Cyclosporine | Tacrolimus |
|---|---|---|
| Number of Participants With Viral Relapse | 0 | 0 |
Collected over Up to 52 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporine | — | 4/10 (40%) | 10/10 (100%) |
| Tacrolimus | — | 4/25 (16%) | 23/25 (92%) |
| Event | Cyclosporine | Tacrolimus |
|---|---|---|
| PyrexiaGeneral disorders | 3/10 | 0/25 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/25 |
| Escherichia Urinary Tract InfectionInfections and infestations | 1/10 | 0/25 |
| Genital HerpesInfections and infestations | 1/10 | 0/25 |
| Facial Bones FractureInjury, poisoning and procedural complications | 1/10 | 0/25 |
| SyncopeNervous system disorders | 1/10 | 0/25 |
| Acute Kidney InjuryRenal and urinary disorders | 1/10 | 0/25 |
| Renal ImpairmentRenal and urinary disorders | 1/10 | 0/25 |
| ProstatitisReproductive system and breast disorders | 1/10 | 0/25 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/10 | 0/25 |
| Event | Cyclosporine | Tacrolimus |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 7/10 | 11/25 |
| AstheniaGeneral disorders | 5/10 | 7/25 |
| FatigueGeneral disorders | 2/10 | 1/25 |
| HyperbilirubinaemiaHepatobiliary disorders | 2/10 | 2/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/10 | 3/25 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/10 | 1/25 |
| PruritusSkin and subcutaneous tissue disorders | 1/10 | 5/25 |
| HeadacheNervous system disorders | 1/10 | 4/25 |
| VertigoEar and labyrinth disorders | 0/10 | 3/25 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 3/25 |
| Age, Continuous(years) | Cyclosporine | Tacrolimus | Total |
|---|---|---|---|
| Median | 64.5 (52 to 69) | 61 (27 to 69) | 62 (27 to 69) |
| Sex: Female, Male(Participants) | Cyclosporine | Tacrolimus | Total |
|---|---|---|---|
| Female | 4 | 9 | 13 |
| Male | 6 | 16 | 22 |
| Region of Enrollment(Participants) | Cyclosporine | Tacrolimus | Total |
|---|---|---|---|
| Germany | 1 | 6 | 7 |
| Spain | 3 | 9 | 12 |
| Poland | 0 | 7 | 7 |
| Italy | 6 | 3 | 9 |
Ran from Dec 2013 to primary completion in Apr 2015, 16 months.
Results were first posted in Nov 2018, 3 years 6 months after primary completion. A results delay was requested in Apr 2016.
Of 28 industry-sponsored phase 2 interventional studies under Hepatitis C, Chronic, half reached primary completion within 16 months of starting (the median); a quarter within 10 and three quarters within 28. This study's 16 months is close to that.
Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Simeprevir · Daclatasvir · Ribavirin